InterCure Ltd. (INCR) 股票分析

公司概述

InterCure Ltd. (NYSE: INCR) operates within the healthcare sector, specifically classified under drug manufacturing for specialty and generic pharmaceuticals, focusing on the cultivation, production, and distribution of pharmaceutical-grade cannabis. The company's business model encompasses the research and development of cannabis-based products intended for medical use, serving both the Israeli domestic market and international clients. As of the latest available data, the firm maintains a market capitalization of $41.56 million and employs a workforce of 320 individuals. The current market cap and reported revenue figures indicate that the company operates as a micro-cap entity with a relatively small market footprint compared to large-cap pharmaceutical peers. This valuation scale suggests that the company is likely in a growth or early-stage commercialization phase where capital allocation priorities differ from established, cash-flow-positive industry leaders.

财务健康

The company reports a trailing twelve-month revenue figure of N/A and a net income of N/A, while the EBITDA stands at -$80,619,000, indicating a significant gap between top-line revenue generation and bottom-line profitability. The absence of reported revenue and net income figures in the provided data precludes a direct calculation of gross margins, though the reported gross margin is 16.7%, which typically suggests that the cost of goods sold consumes a substantial portion of sales revenue before operating expenses are deducted. The operating margin is recorded at 0.0%, reflecting that operating expenses have fully consumed gross profits, while the profit margin is -29.2%, signaling a loss on every dollar of sales. Free cash flow is reported at -$18,398,624, which implies a lack of financial flexibility and a reliance on external capital sources to fund ongoing operations and capital expenditures. The balance sheet presents a complex picture as cash figures are not disclosed, but the debt-to-equity ratio is high at 41.49, suggesting a highly leveraged capital structure rather than a conservative one. Despite the high leverage, the current ratio stands at 1.85, indicating that the company possesses sufficient current assets to cover its short-term liabilities with a buffer of 85%. Return on equity is -16.7% and return on assets is -7.7%, metrics that reveal management is currently unable to generate positive returns on the capital invested by shareholders or the company's total asset base.

估值评估

The trailing P/E ratio is N/A due to the lack of net income, while the forward P/E is calculated at -0.51, a negative figure that implies earnings are not expected to be positive in the immediate future based on current analyst projections or company guidance. The price-to-book ratio is 0.10, indicating that the market values the company at only 10% of its book value, which often suggests significant distress or a market perception that the company's assets are overvalued on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are listed as N/A or unavailable in the provided facts, preventing a direct comparison with revenue-generative peers on a sales or enterprise value basis. The stock's 52-week trading range spans from a low of $0.68 to a high of $1.77, and without the specific current share price in the data source, the exact percentage deviation from these bounds cannot be calculated, though the trading band defines the historical volatility envelope. The beta value is 0.33, which indicates that the stock's price volatility is significantly lower than that of the broader market, moving at roughly one-third the amplitude of the market index during periods of systemic risk.

Growth & Income

Revenue growth year-over-year is recorded at 3.4%, while earnings growth is N/A, a discrepancy that highlights the company's inability to convert revenue increases into net income growth due to underlying cost structures or operating losses. Since the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, meaning that instead of distributing cash to shareholders, the firm retains all earnings—or rather, absorbs all losses—to fund its research, cultivation, and distribution operations. This reinvestment strategy is typical for pre-revenue or early-stage biotech and cannabis firms that prioritize expanding their product portfolio over providing current income to investors. The overall growth and income profile is characterized by modest top-line expansion coupled with significant operating losses and a lack of dividend income, reflecting a high-risk, high-reward dynamic common in the specialty cannabis manufacturing sector.